Cargando…

A cold spot compensation technique using a combination of trans-rectal ultrasonography and intraoperative computed tomography for interstitial permanent prostate brachytherapy: a single-arm prospective trial

PURPOSE: To evaluate the efficacy of a cold spot compensation technique using a combination of trans-rectal ultrasonography (TRUS) and computed tomography (CT) for permanent interstitial prostate brachytherapy. MATERIAL AND METHODS: Sixty-five patients were treated with the cold spot compensation te...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishiyama, Hiromichi, Tsumura, Hideyasu, Kawakami, Shogo, Satoh, Takefumi, Sekiguchi, Akane, Tabata, Ken-ichi, Iwamura, Masatsugu, Hayakawa, Kazushige
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881599/ https://www.ncbi.nlm.nih.gov/pubmed/29619051 http://dx.doi.org/10.5114/jcb.2018.74319

Ejemplares similares

Comparison of prostate contours between conventional stepping transverse imaging and Twister-based sagittal imaging in permanent interstitial prostate brachytherapy
por: Kawakami, Shogo, et al.
Publicado: (2017)

Dosimetry of permanent interstitial prostate brachytherapy for an interoperative procedure, using O-arm based CT and TRUS
por: Ishiyama, Hiromichi, et al.
Publicado: (2016)

Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2017)

(125)Iodine monotherapy for Japanese men with low- and intermediate-risk prostate cancer: outcomes after 5 years of follow-up
por: Sekiguchi, Akane, et al.
Publicado: (2014)

Comparison of three different techniques of low-dose-rate seed implantation for prostate cancer
por: Ishiyama, Hiromichi, et al.
Publicado: (2015)

A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
por: Kainuma, Takuro, et al.
Publicado: (2019)

Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2016)

Catheter displacement prior to the delivery of high-dose-rate brachytherapy in the treatment of prostate cancer patients
por: Kawakami, Shogo, et al.
Publicado: (2014)

High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up
por: Ishiyama, Hiromichi, et al.
Publicado: (2014)

Dosimetric Predictors of Toxicity after Prostate Stereotactic Body Radiotherapy: A Single-Institutional Experience of 145 Patients
por: Fujii, Kyohei, et al.
Publicado: (2023)

Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer
por: Tabata, Ken-ichi, et al.
Publicado: (2012)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
por: Kawakami, S., et al.
Publicado: (2022)

Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer
por: Yanagisawa, Nobuyuki, et al.
Publicado: (2021)

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
por: Koguchi, Dai, et al.
Publicado: (2021)

Assessment of transposed ovarian movement: how much of a safety margin should be added during pelvic radiotherapy?
por: Soda, Itaru, et al.
Publicado: (2015)

Dosimetric factors associated with long-term patient-reported outcomes after definitive radiotherapy of patients with head and neck cancer
por: Hayakawa, Toyokazu, et al.
Publicado: (2019)

Quality of life score as a prognosticator for pharyngeal cancer patients treated with radiotherapy
por: Ishiyama, Hiromichi, et al.
Publicado: (2022)

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
por: Kawahara, Takashi, et al.
Publicado: (2020)

Imaging Cherenkov emission for quality assurance of high-dose-rate brachytherapy
por: Yogo, Katsunori, et al.
Publicado: (2020)

A novel prognostic model for Japanese patients with newly diagnosed bone‐metastatic hormone‐naïve prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study
por: Kawahara, Takashi, et al.
Publicado: (2020)

The phylogeny of permanent prostate brachytherapy
por: Aronowitz, Jesse N., et al.
Publicado: (2013)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
por: Kawahara, Takashi, et al.
Publicado: (2023)

Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer
por: Mori, Kohei, et al.
Publicado: (2023)

Phase IIa Clinical Trial of Trans-1-Amino-3-(18)F-Fluoro-Cyclobutane Carboxylic Acid in Metastatic Prostate Cancer
por: Inoue, Yusuke, et al.
Publicado: (2014)

Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapy
por: Ishiyama, Hiromichi, et al.
Publicado: (2016)

Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients
por: Ishiyama, Hiromichi, et al.
Publicado: (2021)

Permanent Interstitial Brachytherapy for Previously Irradiated Head and Neck Cancer
por: Breen, William, et al.
Publicado: (2018)

Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer
por: Shi, Liangrong, et al.
Publicado: (2012)

Effect of constipation on dosimetry after permanent seed brachytherapy for prostate cancer
por: Otón, L. Fernando, et al.
Publicado: (2015)

A comparative evaluation of loading times and exposures for permanent prostate brachytherapy
por: Bice, W. S., et al.
Publicado: (2002)

Effect of Gold Nanoparticle Radiosensitization on Plasmid DNA Damage Induced by High-Dose-Rate Brachytherapy
por: Yogo, Katsunori, et al.
Publicado: (2021)

Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources
por: Commission Internationale de Protection contre les Radiations
Publicado: (2005)

Stereotactic iodine-125 brachytherapy for brain tumors: temporary versus permanent implantation
por: Ruge, Maximilian I, et al.
Publicado: (2012)

Re-implantation after insufficient primary 125-i permanent prostate brachytherapy
por: Putora, Paul Martin, et al.
Publicado: (2013)

Late seed migration after prostate brachytherapy with Iod-125 permanent implants
por: Maletzki, Philipp, et al.
Publicado: (2018)

Analysis of immune status after iodine-125 permanent brachytherapy in prostate cancer
por: Du, E, et al.
Publicado: (2017)

Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas
por: Wang, Congxiao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iiefptrrd2nuho3j8so7524ll6